<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">lvrach</journal-id><journal-title-group><journal-title xml:lang="ru">Лечащий Врач</journal-title><trans-title-group xml:lang="en"><trans-title>Lechaschi Vrach</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-5175</issn><issn pub-type="epub">2687-1181</issn><publisher><publisher-name></publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51793/OS.2021.24.6.014</article-id><article-id custom-type="elpub" pub-id-type="custom">lvrach-773</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СОБЫТИЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EVENT</subject></subj-group></article-categories><title-group><article-title>Многогранная гиперурикемия: современные подходы к диагностике начиная с бессимптомной стадии и выбору стратегии лечения</article-title><trans-title-group xml:lang="en"><trans-title>Multifaceted hyperuricemia: modern approaches to diagnosis from the asymptomatic stage and the choice of treatment strategy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ковалёва</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kovaleva</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">pract@osp.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Журнал «Лечащий Врач»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>The Lechaschy Vrach Journal</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>21</day><month>07</month><year>2021</year></pub-date><volume>0</volume><issue>6</issue><fpage>64</fpage><lpage>71</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ковалёва И.В., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Ковалёва И.В.</copyright-holder><copyright-holder xml:lang="en">Kovaleva I.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.lvrach.ru/jour/article/view/773">https://journal.lvrach.ru/jour/article/view/773</self-uri><abstract><p>24 мая 2021 г. в рамках IX Евразийского конгресса кардиологов в онлайн-режиме при содействии компании «Эгис» состоялся симпозиум «Многогранная гиперурикемия». Эксперты обсудили ключевые моменты диагностики и лечения бессимптомной и клинически явной гиперурикемии, а также имеющиеся расхождения в зарубежных и российских клинических рекомендациях относительно уровня мочевой кислоты (МК) в сыворотке крови, по достижении которого необходимо начинать медикаментозную терапию. Не остались без внимания и вопросы патогенеза гиперурикемии, ее связь с сахарным диабетом 2 типа, артериальной гипертонией, хронической болезнью почек и рядом других заболеваний. Докладчики подробно остановились на возможностях нормализации показателя МК с помощью диеты и модификации образа жизни (снижения избыточной массы тела, расширения двигательной активности больного) и особо отметили, что комплаентные к терапии пациенты достигают больших успехов в борьбе с гиперурикемией, что может благоприятно повлиять на снижение риска развития ассоциированных с ней заболеваний, в том числе подагры, нефролитиаза, хронической почечной недостаточности и др.</p></abstract><trans-abstract xml:lang="en"><p>On May 24, 2021, within the framework of the IX Eurasian Congress of Cardiology, a symposium «Multifaceted Hyperuricemia»was held online with the assistance of the Egis company. The experts discussed the key points in the diagnosis and treatment of asymptomatic and clinically overt hyperuricemia, as well as the existing discrepancies in foreign and Russian clinical guidelines regarding the level of uric acid in the blood serum, upon reaching which it is necessary to start drug therapy. The questions of the pathogenesis of hyperuricemia, its connection with type 2 diabetes mellitus, arterial hypertension, chronic kidney disease and a number of other diseases were not ignored. The speakers dwelt in detail on the possibilities of normalizing the uric acid indicator through diet and lifestyle modifications (reducing excess body weight, expanding the patient's motor activity) and especially noted that patients who are compliant with therapy achieve great success in the fight against hyperuricemia, which can have a beneficial effect on reducing the risk of developing diseases associated with it, including gout, nephrolithiasis, chronic renal failure, etc.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>конгресс кардиологов</kwd><kwd>гиперурикемия</kwd><kwd>мочевая кислота</kwd><kwd>подагра</kwd><kwd>нефролитиаз</kwd><kwd>диета</kwd><kwd>клинические рекомендации</kwd></kwd-group><kwd-group xml:lang="en"><kwd>congress of cardiologists</kwd><kwd>hyperuricemia</kwd><kwd>uric acid</kwd><kwd>gout</kwd><kwd>nephrolithiasis</kwd><kwd>diet</kwd><kwd>clinical guidelines</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова Е. И., Жернакова Ю. В., Кисляк О. А., Недогода С. В. и соавт. Консенсус по ведению пациентов с гипеурикемией и высоким сердечнососудистым риском // Системные гипертензии. 2019; 16 (4): 8-21. https://cyberleninka.ru/article/n/konsensus-po-vedeniyu-patsientov-s-giperurikemieyi-vysokim-serdechno-sosudistym-riskom/viewer. [Chazova Ye. I., Zhernakova Yu. V., Kislyak O. A., Nedogoda S. V. i soavt. Konsensus po vedeniyu patsiyentov s gipeurikemiyey i vysokim serdechnososudistym riskom. [Nedogoda et al. Consensus on the management of patients with hyperuricemia and high cardiovascular risk.] Sistemnyye gipertenzii. 2019; 16 (4): 8-21. https://cyberleninka.ru/article/n/konsensus-po-vedeniyu-patsientov-s-giperurikemiey-i-vysokim-serdechno-sosudistym-riskom/viewer.]</mixed-citation><mixed-citation xml:lang="en">Чазова Е. И., Жернакова Ю. В., Кисляк О. А., Недогода С. В. и соавт. Консенсус по ведению пациентов с гипеурикемией и высоким сердечнососудистым риском // Системные гипертензии. 2019; 16 (4): 8-21. https://cyberleninka.ru/article/n/konsensus-po-vedeniyu-patsientov-s-giperurikemieyi-vysokim-serdechno-sosudistym-riskom/viewer. [Chazova Ye. I., Zhernakova Yu. V., Kislyak O. A., Nedogoda S. V. i soavt. Konsensus po vedeniyu patsiyentov s gipeurikemiyey i vysokim serdechnososudistym riskom. [Nedogoda et al. Consensus on the management of patients with hyperuricemia and high cardiovascular risk.] Sistemnyye gipertenzii. 2019; 16 (4): 8-21. https://cyberleninka.ru/article/n/konsensus-po-vedeniyu-patsientov-s-giperurikemiey-i-vysokim-serdechno-sosudistym-riskom/viewer.]</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Шальнова С. А., Деев А. Д., Артамонова Г. В., Дупляков Д. В. и соавт. Гиперурикемия и ее корреляты в Российской популяции (результаты эпидемиологического исследования ЭССЕ РФ) // Рациональная фармакотерапия в кардиологии. 2014; 10 (2): 153-159. https://www.rpcardio.com/jour/article/view/16?locale=ru_RU. [Shal'nova S. A., Deyev A. D., Artamonova G. V., Duplyakov D. V. i soavt. Giperurikemiya i yeye korrelyaty v Rossiyskoy populyatsii (rezul'taty epidemiologicheskogo issledovaniya ESSE RF). [Hyperuricemia and its correlates in the Russian population (results of an epidemiological study by ESSE RF)] Ratsional'naya farmakoterapiya v kardiologii. 2014; 10 (2): 153-159. https://www.rpcardio.com/jour/article/view/16?locale=ru_RU.]</mixed-citation><mixed-citation xml:lang="en">Шальнова С. А., Деев А. Д., Артамонова Г. В., Дупляков Д. В. и соавт. Гиперурикемия и ее корреляты в Российской популяции (результаты эпидемиологического исследования ЭССЕ РФ) // Рациональная фармакотерапия в кардиологии. 2014; 10 (2): 153-159. https://www.rpcardio.com/jour/article/view/16?locale=ru_RU. [Shal'nova S. A., Deyev A. D., Artamonova G. V., Duplyakov D. V. i soavt. Giperurikemiya i yeye korrelyaty v Rossiyskoy populyatsii (rezul'taty epidemiologicheskogo issledovaniya ESSE RF). [Hyperuricemia and its correlates in the Russian population (results of an epidemiological study by ESSE RF)] Ratsional'naya farmakoterapiya v kardiologii. 2014; 10 (2): 153-159. https://www.rpcardio.com/jour/article/view/16?locale=ru_RU.]</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">The results of PolSenior Stady // Int J Environ Res Public Health. 2021; 18: 387.</mixed-citation><mixed-citation xml:lang="en">The results of PolSenior Stady // Int J Environ Res Public Health. 2021; 18: 387.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Паскарь Н. А. Опыт ведения «Регистра АГ» и проведения клинического аудита медицинской помощи больным артериальной гипертензией // Вестник СПбГУ. 2014; 11 (3): 65-73. https://cyberleninka.ru/article/n/opyt-vedeniya-registra-ag-i-provedeniya-klinicheskogo-audita-meditsinskoypomoschi-bolnym-arterialnoy-gipertenziey. [Paskar' N. A. Opyt vedeniya «Registra AG» i provedeniya klinicheskogo audita meditsinskoy pomoshchi bol'nym arterial'noy gipertenziyey. [Experience in maintaining the "Register of hypertension" and conducting a clinical audit of medical care for patients with arterial hypertension.] Vestnik SPbGU. 2014; 11 (3): 65-73. https://cyberleninka.ru/article/n/opyt-vedeniya-registra-ag-i-provedeniya-klinicheskogo-audita-meditsinskoy-pomoschi-bolnym-arterialnoy-gipertenziey.]</mixed-citation><mixed-citation xml:lang="en">Паскарь Н. А. Опыт ведения «Регистра АГ» и проведения клинического аудита медицинской помощи больным артериальной гипертензией // Вестник СПбГУ. 2014; 11 (3): 65-73. https://cyberleninka.ru/article/n/opyt-vedeniya-registra-ag-i-provedeniya-klinicheskogo-audita-meditsinskoypomoschi-bolnym-arterialnoy-gipertenziey. [Paskar' N. A. Opyt vedeniya «Registra AG» i provedeniya klinicheskogo audita meditsinskoy pomoshchi bol'nym arterial'noy gipertenziyey. [Experience in maintaining the "Register of hypertension" and conducting a clinical audit of medical care for patients with arterial hypertension.] Vestnik SPbGU. 2014; 11 (3): 65-73. https://cyberleninka.ru/article/n/opyt-vedeniya-registra-ag-i-provedeniya-klinicheskogo-audita-meditsinskoy-pomoschi-bolnym-arterialnoy-gipertenziey.]</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">The results of NHANES STUDY // Arthritis Rheum. 2011; 63: 345-349.</mixed-citation><mixed-citation xml:lang="en">The results of NHANES STUDY // Arthritis Rheum. 2011; 63: 345-349.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hyperuricemia and cardiovascular diseases. The Rotterdam Study // Stroke. 2006; 37: 548-569.</mixed-citation><mixed-citation xml:lang="en">Hyperuricemia and cardiovascular diseases. The Rotterdam Study // Stroke. 2006; 37: 548-569.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lijun Li, Maoxiang Zhao, Chi Wang et al. Early onset of huperuricemia is associated with increased cardiovascular disease and mortality risk // Clinical Research of Cardiology. 2021: 1: 15-24.</mixed-citation><mixed-citation xml:lang="en">Lijun Li, Maoxiang Zhao, Chi Wang et al. Early onset of huperuricemia is associated with increased cardiovascular disease and mortality risk // Clinical Research of Cardiology. 2021: 1: 15-24.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И. Е., Жернакова Ю. В от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии // Системные гипертензии. 2019; 16 (1): 6-31. DOI: 10.26442/2075082X.2019.1.190179. [Chazova I. Ye., Zhernakova Yu. V. ot imeni ekspertov. Klinicheskiye rekomendatsii. Diagnostika i lecheniye arterial'noy gipertonii. [Clinical guidelines. Diagnostics and treatment of arterial hypertension.] Sistemnyye gipertenzii 2019; 16 (1): 6-31. DOI: 10.26442/2075082X.2019.1.190179]</mixed-citation><mixed-citation xml:lang="en">Чазова И. Е., Жернакова Ю. В от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии // Системные гипертензии. 2019; 16 (1): 6-31. DOI: 10.26442/2075082X.2019.1.190179. [Chazova I. Ye., Zhernakova Yu. V. ot imeni ekspertov. Klinicheskiye rekomendatsii. Diagnostika i lecheniye arterial'noy gipertonii. [Clinical guidelines. Diagnostics and treatment of arterial hypertension.] Sistemnyye gipertenzii 2019; 16 (1): 6-31. DOI: 10.26442/2075082X.2019.1.190179]</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Grayson P. C., Kim S. Y., LaValley M. et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis // Arthritis Care Res (Hoboken). 2011; 63 (1): 102-110. DOI: 10.1002//acr.20344, indexed in PubMed: 20824805.</mixed-citation><mixed-citation xml:lang="en">Grayson P. C., Kim S. Y., LaValley M. et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis // Arthritis Care Res (Hoboken). 2011; 63 (1): 102-110. DOI: 10.1002//acr.20344, indexed in PubMed: 20824805.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kuwabara M., Borghi C., Cicero A. F. G. et al. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan // Int J Cardiol. 2018; 261: 183-188, indexed in Pubmed: 29551256.</mixed-citation><mixed-citation xml:lang="en">Kuwabara M., Borghi C., Cicero A. F. G. et al. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan // Int J Cardiol. 2018; 261: 183-188, indexed in Pubmed: 29551256.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Bombelli M., Toso E., Peronio M., Fordi D. The Pamela Study main findings and perspectives // Current Hypertension Reports. 2013; 15 (3): 18-27. https://www.researchgate.net/publication/236266655_The_Pamela_Study_Main_Findings_and_Perspectives.</mixed-citation><mixed-citation xml:lang="en">Bombelli M., Toso E., Peronio M., Fordi D. The Pamela Study main findings and perspectives // Current Hypertension Reports. 2013; 15 (3): 18-27. https://www.researchgate.net/publication/236266655_The_Pamela_Study_Main_Findings_and_Perspectives.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Бадокин В. В. Диагностика и лечение подагрического артрита // Лечащий Врач. 2004; 7: 31-39. https://www.lvrach.ru/2004/07/4531505. [Badokin V. V. Diagnostika i lecheniye podagricheskogo artrita. [Diagnosis and treatment of gouty arthritis.] The Lechaschi Vrach Journal. 2004; 7: 31-9. https://www.lvrach.ru/2004/07/4531505.]</mixed-citation><mixed-citation xml:lang="en">Бадокин В. В. Диагностика и лечение подагрического артрита // Лечащий Врач. 2004; 7: 31-39. https://www.lvrach.ru/2004/07/4531505. [Badokin V. V. Diagnostika i lecheniye podagricheskogo artrita. [Diagnosis and treatment of gouty arthritis.] The Lechaschi Vrach Journal. 2004; 7: 31-9. https://www.lvrach.ru/2004/07/4531505.]</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Maloberti A., Bombelli M., Rita Facchetti et al. Relationships between diureticrelated hyperuricemia and cardiovascular events: data from the Uric acid Right for heArt Health study // J. Hypertension. 2021; 2 (39): 156-163.</mixed-citation><mixed-citation xml:lang="en">Maloberti A., Bombelli M., Rita Facchetti et al. Relationships between diureticrelated hyperuricemia and cardiovascular events: data from the Uric acid Right for heArt Health study // J. Hypertension. 2021; 2 (39): 156-163.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Farquharson C. A. et al. Allopurinol improves endothelial dysfunction in chronic heart failure // Circulation. 2002; 106 (2): 221-226.</mixed-citation><mixed-citation xml:lang="en">Farquharson C. A. et al. Allopurinol improves endothelial dysfunction in chronic heart failure // Circulation. 2002; 106 (2): 221-226.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">White W. B., Saag K. G., Becker M. A. et al. Cardiovascular safety of Febuxostat or Allopurinol in patiens with gout // New England J. Med. 2018; 11 (1): 22-26.</mixed-citation><mixed-citation xml:lang="en">White W. B., Saag K. G., Becker M. A. et al. Cardiovascular safety of Febuxostat or Allopurinol in patiens with gout // New England J. Med. 2018; 11 (1): 22-26.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Barrientos-Regala M., Pestano N. S., Punzalan F. E. R. et al. The association of Febuxostat compared with Allopurinol on blood pressure and major adverse cardiac events among adult patients with hyperuricemia: a meta-analysis // J. Cardiovasc Pharmacolog. 2020; 76 (4): 461-471. https://pubmed.ncbi.nlm.nih.gov/32675751/.</mixed-citation><mixed-citation xml:lang="en">Barrientos-Regala M., Pestano N. S., Punzalan F. E. R. et al. The association of Febuxostat compared with Allopurinol on blood pressure and major adverse cardiac events among adult patients with hyperuricemia: a meta-analysis // J. Cardiovasc Pharmacolog. 2020; 76 (4): 461-471. https://pubmed.ncbi.nlm.nih.gov/32675751/.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Yang W. X., Ma Y., Hau Y. L., Wang Y. B. et al // Clin Lab. 2019; 65 (8): 10.7754.</mixed-citation><mixed-citation xml:lang="en">Yang W. X., Ma Y., Hau Y. L., Wang Y. B. et al // Clin Lab. 2019; 65 (8): 10.7754.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Chen-Xu M., Yakose C., Rai S. K. et al. // Arthritis Reumatol. 2019; 71: 991-999.</mixed-citation><mixed-citation xml:lang="en">Chen-Xu M., Yakose C., Rai S. K. et al. // Arthritis Reumatol. 2019; 71: 991-999.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Shimazaki S., Kazukawa I., Mori K., Kihara M., Minagawa M. Acute kidney injury caused by ammonium acid urate crystals in diabetic ketoacidosis at the onset of type 1 diabetes mellitus // Endocrinol Diabetes Metab Case Rep. 2021 Feb 26; 2021: EDM200143. DOI: 10.1530/EDM-20-0143. Online.</mixed-citation><mixed-citation xml:lang="en">Shimazaki S., Kazukawa I., Mori K., Kihara M., Minagawa M. Acute kidney injury caused by ammonium acid urate crystals in diabetic ketoacidosis at the onset of type 1 diabetes mellitus // Endocrinol Diabetes Metab Case Rep. 2021 Feb 26; 2021: EDM200143. DOI: 10.1530/EDM-20-0143. Online.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Fagundes A. C., de Oliveira E. D., Ferrari S. G. et al. Allopurinol for fibromialgia pain in adults: a randomized controlled trial // Pain Pract. 2021; Apr. 17. DOI: 10.1111/papr.13019/ Online ahead of print.</mixed-citation><mixed-citation xml:lang="en">Fagundes A. C., de Oliveira E. D., Ferrari S. G. et al. Allopurinol for fibromialgia pain in adults: a randomized controlled trial // Pain Pract. 2021; Apr. 17. DOI: 10.1111/papr.13019/ Online ahead of print.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Hu Y., Chan Z., Li C. et al. Higher serum uric acid levels are associated with an increased risk of vision-threatening diabetic retinopathy in type 2 diabetes patients // Invest Ophtalmol Vis Sci. 2021; Apr. 1; 62 (4): 23. DOI: 10.1167/iovs.62.4.23.</mixed-citation><mixed-citation xml:lang="en">Hu Y., Chan Z., Li C. et al. Higher serum uric acid levels are associated with an increased risk of vision-threatening diabetic retinopathy in type 2 diabetes patients // Invest Ophtalmol Vis Sci. 2021; Apr. 1; 62 (4): 23. DOI: 10.1167/iovs.62.4.23.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">E79.0 Гиперурикемия без признаков воспалительного артрита и подагрических узлов // Электронная энциклопедия лекарств РЛС: https://www.rlsnet.ru/mkb_index_id_2325.htm. [E79.0 Giperurikemiya bez priznakov vospalitel'nogo artrita i podagricheskikh uzlov. [E79.0 Hyperuricemia without signs of inflammatory arthritis and gouty nodes.] Elektronnaya entsiklopediya lekarstv RLS https://www.rlsnet.ru/mkb_index_id_2325.htm.]</mixed-citation><mixed-citation xml:lang="en">E79.0 Гиперурикемия без признаков воспалительного артрита и подагрических узлов // Электронная энциклопедия лекарств РЛС: https://www.rlsnet.ru/mkb_index_id_2325.htm. [E79.0 Giperurikemiya bez priznakov vospalitel'nogo artrita i podagricheskikh uzlov. [E79.0 Hyperuricemia without signs of inflammatory arthritis and gouty nodes.] Elektronnaya entsiklopediya lekarstv RLS https://www.rlsnet.ru/mkb_index_id_2325.htm.]</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Genome-wide association studies (GWAS): https://www.ebi.ac.uk/gwas/home.</mixed-citation><mixed-citation xml:lang="en">Genome-wide association studies (GWAS): https://www.ebi.ac.uk/gwas/home.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Tin F. et al. Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels // Nat Genet. 2019: 51, 1459-1474. https://www.nature.com/articles/s41588-019-0504-x.</mixed-citation><mixed-citation xml:lang="en">Tin F. et al. Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels // Nat Genet. 2019: 51, 1459-1474. https://www.nature.com/articles/s41588-019-0504-x.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
